COMMON STOCK PURCHASE WARRANT NKGEN BIOTECH, INC.Security Agreement • August 9th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances)
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the unsecured promissory note in the principal amount of $2,750,000.00 to the Holder (as defined below) of even date) (the “Note”), CFIC-2015 NV FAMILY INVESTMENTS, LLC (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from NKGEN BIOTECH, INC., a Delaware corporation (the “Company”), 2,750,000 shares of Common Stock (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated August 7, 2024, by and among the Company and the Holder (the
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 9th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
SECOND LETTER AGREEMENT REGARDING UNSECURED NOTESecond Letter Agreement Regarding Unsecured Note • August 9th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This Second Letter Agreement (“Letter”), dated as of August 7, 2024, is made between Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Capital, LLC (collectively, “Lender”) and NKGEN BIOTECH, INC. (“Borrower”).
LETTER AGREEMENT REGARDING SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 9th, 2024 • NKGen Biotech, Inc. • Biological products, (no disgnostic substances)
This Letter Agreement (“Letter”), dated as of August 7, 2024, is made between CFIC-2015 NV FAMILY INVESTMENTS, LLC (the “Buyer”) and NKGEN BIOTECH, INC. (the “Company”).
